论文部分内容阅读
目的 了解肿瘤患者体内分离出的肠杆菌产生超广谱β—内酰胺酶的机理、耐药特征以及耐药菌株的来源,从而指导临床用药。方法 对本院1999年2～12月108名住院患者血、尿、痰标本中分离出的肺炎克雷伯氏菌、大肠埃希氏菌进行了分析,用琼脂扩散法测定标本对8种β—内酰胺类抗生素的敏感性,检出产生超广谱酶的菌株。结果 肿瘤患者体内分离出的肺炎克雷伯氏菌、大肠埃希氏菌产生超广谱β—内酰胺酶的菌株高达56.48％。结论 肿瘤患者产生超广谱β—内酰胺酶明显高于非肿瘤患者井有院内爆发流行的趋势。
Objective To understand the mechanism of the production of extended-spectrum β-lactamase isolated from tumor patients, the characteristics of drug resistance, and the origin of drug-resistant strains, so as to guide clinical drug use. Methods Klebsiella pneumoniae and Escherichia coli isolated from blood, urine and sputum specimens of 108 inpatients from February to December in 1999 were analyzed. Samples were measured by agar diffusion method for 8 betas. - The sensitivity of lactam antibiotics to detect strains that produce an extended-spectrum enzyme. Results The strains isolated from tumor patients with Klebsiella pneumoniae and Escherichia coli produced extended spectrum β-lactamase up to 56.48%. Conclusion The production of extended-spectrum β-lactamase in tumor patients is significantly higher than that in non-tumor patients.